Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

MELBOURNE, Australia, Oct. 5 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) ("Cytopia") has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia. This transaction will be conducted by scheme(s) of arrangement ("Scheme(s)") and shareholders (and optionholders if required)(i) are expected to vote on the Scheme(s) in January 2010.

Cytopia shareholders will be offered 1 YM share for every 11.737 Cytopia shares.(ii) Cytopia option holders will receive YM options at an equivalent ratio. The Share Scheme consideration represents a share price offer of $0.1659 per Cytopia share. This is a 58 % premium to the trading price of Cytopia shares on the ASX immediately prior to signing of the Agreement. The consideration payable will be subject to an arrangement providing for adjustments to the share exchange ratio where there are significant movements in the trading price of YM shares.

YM has a market capitalisation of approximately C$87 million, with approximately 58.2 million shares on issue, and a closing price of C$1.49 on the Toronto Stock Exchange on 5 October 2009. In its most recent published accounts for the year ended 30 June 2009, YM reported cash and cash equivalents of approximately C$41 million. On successful implementation of the Schemes, Cytopia shareholders should own approximately 11% of YM.

YM is a clinical stage cancer-focused life sciences company with its lead drug candidate nimotuzumab in development world wide in numerous Phase II and Phase III clinical trials. The drug has marketing approval in 21 countries. The company has offices in Canada, USA, United Kingdom and Cuba and is listed on the Toronto Stock Exchange (YM) and the New York Stock Exchange/AMEX (YMI).

Post implementation, the combined comp
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
2. Cytopia Presentation on VDA CYT997 at AACR Conference
3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
4. Cytopia Letter to Progen Shareholders
5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
10. Schering-Plough Shareholders Approve Merger With Merck
11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)... RMI specializes in ... conditions such as meniscal tears, ACL injuries, rotator ... pain due to degenerative conditions like osteoarthritis. ... to promote better post-surgical outcomes. , Stemnexa combines ... bone marrow harvesting with two complimentary cellular technologies: ...
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 ... in Personalized Medicine, is excited to announce the ... Testing to Optimize the Management of Pain”. , ... at Medscape.com for the next year. The focus ... how to recognize inadequate pain treatments, integrate appropriate ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3
... now at 15, SANTA CRUZ, Calif., Sept. 30 ... board and careers tool site for life-science,professionals, Bio Career ... two new schools -- the University of Texas M.,D. ... adding these two schools to the site, we are ...
... Inc. (OTC,Bulletin Board: BTEL) announced results for the year ... $0.23 per diluted share, on revenues of,$11,495,000. This compares ... revenues of $11,233,000 for the prior year. For its ... $0.07 per diluted share, on,revenues of $3,187,000. This compares ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ... U.S. Patent 7,429,485 entitled "Method of Producing ... reassorted reovirus from,an FDA-approved cell line., ... of producing,reassorted reovirus," said Mary Ann Dillahunty, ...
Cached Biology Technology:Two Top-Ranking Schools Join Jobs Board Site 2Biotel Announces Record Revenues and Earnings for Fiscal 2008 2Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent 2
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)...   Neurotechnology , a provider of high-precision biometric, ... Software Development Kit (SDK). The SentiGaze algorithm enables ... webcams to track eye movements and generate heatmaps based ... can be used for applications such as analysis of ... SDK can also be used to develop interfaces for ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... the western Antarctic Peninsula since 1850 The ... over the past 50 years (the period of observational ... on the fringes of the peninsula disintegrating. Despite this, ... of days with snowfall has increased by at least ...
... MD The Biophysical Society has announced the speakers for ... of the Biophysical Society and the International Biophysics Congress ... The new and notable symposium highlights the latest and ... and selected by the Societys program committee. The ...
... is a tiny yet insidious waterborne parasite that wreaks ... diarrhea and malnutrition in small children in developing countries, ... compromised patients in the developed world. Cryptosporidium is resistant ... the U.S., which has led to the concern that ...
Cached Biology News:AGU journal highlights -- Jan. 28, 2008 2AGU journal highlights -- Jan. 28, 2008 3AGU journal highlights -- Jan. 28, 2008 4AGU journal highlights -- Jan. 28, 2008 5AGU journal highlights -- Jan. 28, 2008 6Biophysical Society announces new and notable symposium speakers 2Breakthrough research turns the tide on water-borne pathogen 2
... Exonuclease III digests duplex DNA in a ... 5'-overhang or nick, producing stretches of single-stranded ... by Exonuclease III proceeds at a uniform ... the rate of exonucleolytic excision of deoxyribonucleotides ...
... Klenow fragment is a ... coli DNA Polymerase I ... -> 5 exonuclease activity, but ... activity. Klenow retains the polymerization ...
... degrades, as an endoribonuclease, the RNA ... of natural origin, e.g. that of ... e.g. poly(A) x poly(dT). RNase H ... termini. Nearly no activity is detected ...
... E. coli strain containing an overproducing clone of ... the formation of a phosphodiester bond between juxtaposed ... DNA or RNA. It repairs single-stranded nicks in ... join both blunt-end and cohesive-end fragments of duplex ...
Biology Products: